Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DDF's New CSO Will Get Dementia Discovery 'Out Of A Rut'

This article was originally published in Scrip

Executive Summary

The UK-based Dementia Discovery Fund's first investment was a bit of let-down for academic scientists as it went to an established US biotech company. But this could all change with the appointment of chief scientific officer Dr Tetsuyuki Maruyama (formerly Paul Chapman), who will start his new job in April. Despite a strong pharma executive background, his origins as an academic neuroscientist ensure he knows exactly what is being expected of him by the academic masses.

Related Content





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts